Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada

BACKGROUND AND OBJECTIVES: Ulcerative colitis is highly prevalent in Canada and cost-effective ulcerative colitis therapies are warranted. Vedolizumab subcutaneous (SC) formulation was recently approved for ulcerative colitis maintenance therapy. We assessed vedolizumab SC cost effectiveness vs conv...

Descripción completa

Detalles Bibliográficos
Autores principales: Fenu, Elisabetta, Lukyanov, Vasily, Acs, Annabel, Radu, Xenia, Stypa, Stephanie, Fischer, Aren, Marshall, John K., Oppe, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283596/
https://www.ncbi.nlm.nih.gov/pubmed/35474178
http://dx.doi.org/10.1007/s41669-022-00331-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283596/
https://www.ncbi.nlm.nih.gov/pubmed/35474178
http://dx.doi.org/10.1007/s41669-022-00331-9

Ejemplares similares